EQS-News: Vivoryon Therapeutics N.V. / Key word(s): ConferenceVivoryon Therapeutics N.V.: Vivoryon Therapeutics to Present a Clinical Update on its Novel Oral Small Molecule Varoglutamstat at Clinical Trials on Alzheimer's Disease Conference (CTAD) (...)

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): MiscellaneousVivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares (news with additional features)23.11.2022 / 07:00 CET/CESTThe issuer is solely responsible (...)

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): 9 Month figuresVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress (news with additional features)22.11.2022 / 07:20 (...)

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): MiscellaneousVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022 14.11.2022 / 07:00 CET/CESTThe issuer is solely (...)

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Half Year ResultsVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress (news with additional features)30.09.2022 / 08:47 CET/CESTThe (...)

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Capital IncreaseVivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million (news with additional features)30.09.2022 / 08:45 CET/CESTThe issuer is (...)

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): MiscellaneousVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022 26.09.2022 / 07:00 CET/CESTThe issuer is solely (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): StudyVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022 (news with additional features)31.07.2022 (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study results/StudyVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Research UpdateVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2b Study of Varoglutamstat in AD (news with additional (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGMVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022 (news with additional features)22.06.2022 / 19:13 The issuer is solely responsible for the (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Interim ReportVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q1 2022 Financial Results and Highlights Operational Progress (news with additional features)15.06.2022 / 07:00 The issuer (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): MiscellaneousVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report First Quarter 2022 Financial Results on June 15, 2022 08.06.2022 / 07:00 The issuer is solely responsible for the content (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGMVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022 (news with additional features)11.05.2022 / 07:00 The issuer is solely responsible (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Annual Results/Annual ReportVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Full Year 2021 Financial Results and Highlights Operational Progress (news with additional features)28.04.2022 (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Annual ResultsVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022 21.04.2022 / 07:00 The issuer is solely responsible (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): ConferenceVivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate at Upcoming Investor Conferences 20.04.2022 / 12:01 The issuer is solely responsible for the content of this announcement.Vivoryon (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Capital Increase01.04.2022 / 08:47 The issuer is solely responsible for the content of this announcement.NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Capital Increase31.03.2022 / 17:45 The issuer is solely responsible for the content of this announcement.NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Conference07.03.2022 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference HALLE (SAALE) / MUNICH, (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous28.02.2022 / 01:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Conference04.01.2022 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences HALLE (SAALE) (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous22.12.2021 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): 9 Month figures04.11.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics N.V. Reports Q3 2021 Financial Resultsand Highlights Operational Progress HALLE (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous01.11.2021 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics N.V. to Report Third Quarter 2021 Financial Results on November 4, 2021 Halle (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Study18.10.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Half Year Results21.09.2021 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress  (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous14.09.2021 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics N.V. to Publish its Financial Results for H1 2021and Operational Progress Halle (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Conference09.09.2021 / 16:41 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceHalle (Saale) (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous29.06.2021 / 01:11 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Provides Update on Financial GuidanceHalle (Saale) / Munich, Germany, June (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Agreement29.06.2021 / 01:03 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGM28.06.2021 / 18:00 The issuer is solely responsible for the content of this announcement. Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V. HALLE (SAALE) / MUNICH, (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Quarter Results/Quarterly / Interim Statement25.06.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Announces Financial Resultsfor the First (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous31.05.2021 / 18:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Reschedules Reporting of 1st Quarter 2021 and Provides Update for Annual (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGM17.05.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Announces Notice of its Annual General Meeting of Shareholders to be Held (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Annual Results30.04.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics N.V. Reports Full Year 2020 Financial Results English conference (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous14.04.2021 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics N.V. Reschedules the Reporting of the Full Year 2020 Financial Results to (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous01.04.2021 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics to Host Virtual Event on Current Clinical Landscape in Alzheimer's Disease (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGM12.03.2021 / 18:02 The issuer is solely responsible for the content of this announcement.Extraordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.All proposed resolutions approved (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGM29.01.2021 / 18:09 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics N.V. Announces Nominationsto Reappoint Ulrich Dauer as CEO and to Appoint Florian (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Corporate Action06.01.2021 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics N.V. new ISIN code HALLE (SAALE) / MUNICH, Germany, 06 January 2021 (...)

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous16.12.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics N.V. new Home Member State HALLE (SAALE) / MUNICH, Germany, 16 December (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous14.12.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Successful Relocation of Vivoryon Shares Package HALLE (SAALE) / MUNICH, GERMANY, 14 December 2020 (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Corporate Action30.11.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V. HALLE (SAALE) (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): 9 Month figures26.11.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Reports Third Quarter 2020HALLE (SAALE) / MUNICH, Germany, 26 November 2020 (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous19.11.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020HALLE (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): AGM/EGM01.10.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG All proposed resolutions approved with (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): AGM/EGM03.09.2020 / 15:09 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous27.08.2020 / 19:10 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG plans conversion into Naamloze Vennootschap (N.V.) under Dutch law Vivoryon (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Half Year Results27.08.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Reports Financial Results for H1 2020and Provides Corporate Update- Conference (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous20.08.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG to Publish its Half Year 2020 Results on August 27, 2020HALLE (SAALE) / MUNICH, (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous04.08.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Receives IND Approval for Varoglutamstat's (PQ912) Phase 2 Study in Alzheimer's DiseaseHALLE (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Study15.07.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Announces Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer's Disease (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous26.06.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Provides Update on US and EU Alzheimer's Clinical Trial Program with PQ912 Vivoryon (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Quarter Results14.05.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG Reports First Quarter 2020HALLE (SAALE) / MUNICH, Germany, 14 May 2020 (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): AGM/EGM12.05.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG Postpones Annual General Meeting HALLE (SAALE) / Munich, Germany, 12 May 2020 (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous07.05.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG to Publish its First Quarter 2020 Business Updateon May 14, 2020HALLE (SAALE) (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous29.04.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Announces Outcome of Exclusive Option Deal with MorphoSysMorphoSys will not (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Patent16.04.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Annual Results26.03.2020 / 13:10 The issuer is solely responsible for the content of this announcement.CORRECTION: Vivoryon Therapeutics AG Reports Full Year 2019 Financial ResultsThis is a correction (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Annual Results26.03.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics AG Reports Full Year 2019 Financial ResultsConference call and webcast (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous19.03.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG to Publish its Full Year 2019 Resultson March 26, 2020HALLE (SAALE) / MUNICH, (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Study18.03.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Announces Update on Phase 2b Alzheimer's Clinical Trial, VIVIADVivoryon has extended (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Conference03.03.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics to Attend Upcoming Investor ConferencesHALLE (SAALE)/MUNICH, Germany, 3 March 2020 (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Contract14.01.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics and Nordic Bioscience Enter Research and Development CollaborationHALLE (SAALE), (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Conference07.01.2020 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics to Attend 38th Annual J.P. Morgan Healthcare Conference in January 2020HALLE (SAALE), (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous20.12.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics is Included in AScX Index HALLE (SAALE), Germany, 20 December 2019 - Vivoryon (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): 9 Month figures28.11.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Reports Third Quarter 2019HALLE (SAALE), Germany, 28 November 2019 - Vivoryon (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Conference27.11.2019 / 12:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics attends CTAD 2019HALLE (SAALE), Germany, 27 November 2019 - Vivoryon Therapeutics (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous21.11.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG to Publish Third Quarter 2019 Results on November 28, 2019HALLE (SAALE), (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Financing24.10.2019 / 09:02 The issuer is solely responsible for the content of this announcement.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Offer 08.10.2019 / 13:37 The issuer is solely responsible for the content of this announcement.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Half Year Results29.08.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Reports Financial Results for H1 2019and Corporate Update  Conference (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous22.08.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG to Publish its Half Year 2019 Resultson August 29, 2019HALLE (SAALE), Germany, (...)

goetzpartners securities Limited09-Jul-2019 / 12:50 GMT/BSTFree to access research and investor meetings in a post-MiFID2 world.This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Agreement08.07.2019 / 22:01 The issuer is solely responsible for the content of this announcement.MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Letter of Intent27.06.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics AG enters myeloid immune checkpoint drug discovery, and collaborates with (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Agreement18.06.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics mandates goetzpartners as strategic business development advisor for expansion of (...)

goetzpartners securities Limited15-Jun-2019 / 13:34 GMT/BSTFree to access research and investor meetings in a post-MiFID2 world.This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional (...)

DGAP-News: Vivoryon Therapeutics AG / Key word(s): Corporate Action12.06.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Probiodrug AG becomes Vivoryon Therapeutics AGHealthy Aging - Pioneering InnovationHALLE (SAALE), (...)

DGAP-News: Probiodrug AG / Key word(s): AGM/EGM29.05.2019 / 18:00 The issuer is solely responsible for the content of this announcement.Ordinary General Meeting of Shareholders of Probiodrug AGAll proposed resolutions approved with large majorityHALLE (...)

DGAP-News: Probiodrug AG / Key word(s): Quarter Results16.05.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Probiodrug Reports First Quarter 2019 Business UpdateHALLE (SAALE), Germany, 16 May 2019 - Probiodrug AG (Euronext (...)

DGAP-News: Probiodrug AG / Key word(s): Miscellaneous09.05.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Probiodrug AG to Publish its First Quarter 2019 Business Updateon May 16, 2019HALLE (SAALE), Germany, 9 May 2019 (...)

DGAP-News: Probiodrug AG / Key word(s): AGM/EGM18.04.2019 / 15:06 The issuer is solely responsible for the content of this announcement.Probiodrug AG to hold its Ordinary General Meeting of Shareholderson 29 May 2019HALLE (SAALE), Germany, 18 April 2019 (...)

DGAP-News: Probiodrug AG / Key word(s): Capital Increase15.04.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Probiodrug raises EUR 8.2 million in successful private placement of new shares- Consortium of strategic investors (...)

DGAP-News: Probiodrug AG / Key word(s): Capital Increase09.04.2019 / 18:09 The issuer is solely responsible for the content of this announcement.NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIAProbiodrug raises (...)

DGAP-News: Probiodrug AG / Key word(s): Miscellaneous04.04.2019 / 07:00 The issuer is solely responsible for the content of this announcement. Probiodrug AG has mandatedODDO SEYDLER BANK AG as Designated SponsorThe shares are trading on XETRA, the (...)

DGAP-News: Probiodrug AG / Key word(s): Annual Results28.03.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Probiodrug reports full year 2018 financial results- Conference call and webcast (in English) at 3:00 pm CET (...)

DGAP-News: Probiodrug AG / Key word(s): Miscellaneous21.03.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Probiodrug AG to Publish its Full Year 2018 Resultson March 28, 2019HALLE (SAALE), Germany, 21 March 2019 - Probiodrug (...)

goetzpartners securities Limited20-March-2019 / 12:33 GMT/BSTFree to access research and investor meetings in a post-MiFID2 world.This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (...)

DGAP-News: Probiodrug AG / Key word(s): Miscellaneous20.03.2019 / 07:00 The issuer is solely responsible for the content of this announcement.Probiodrug and Alzheimer's Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (...)

DGAP-News: Probiodrug AG / Key word(s): Conference18.12.2018 / 07:00 The issuer is solely responsible for the content of this announcement.Probiodrug to attend J.P. Morgan Healthcare Conference in January 2019 HALLE (SAALE), Germany, 18 December (...)

DGAP-News: Probiodrug AG / Key word(s): Quarter Results29.11.2018 / 07:04 The issuer is solely responsible for the content of this announcement.Probiodrug Reports Third Quarter 2018 Business UpdateHALLE (SAALE), Germany, 29 November 2018 - Probiodrug (...)

goetzpartners securities Limited15-Oct-2018 / 12:46 GMT/BSTFree to access research and investor meetings in a post-MiFID2 world.This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional (...)

goetzpartners securities Limited03-Sep-2018 / 10:23 GMT/BSTFree to access research and investor meetings in a post-MiFID2 world.This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional (...)

goetzpartners securities Limited13-Jul-2018 / 10:27 GMT/BSTFree to access research and investor meetings in a post-MiFID2 world.This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional (...)

goetzpartners securities Limited10-Apr-2018 / 11:41 GMT/BSTFree to access research and investor meetings in a post-MiFID2 worldProbiodrug (PBD-NA): Lifting the veil on Phase IIb designRecommendation: OUTPERFORMTarget Price: EUR71 (adjusted from EUR91)Current (...)

goetzpartners securities Limited01-Dec-2017 / 09:28 GMT/BSTThis equity research note was formally published on 30th November 2017 at 2.30pm.goetzpartners securities review on Probiodrug (PBD-NA): Q3 positive, Phase IIb on trackRecommendation: OUTPERFORMTarget (...)